<DOC>
	<DOCNO>NCT02737397</DOCNO>
	<brief_summary>The purpose study determine safety efficacy combination product prevention veisalgia . Common symptoms veisalgia follow moderate consumption alcohol include headache , fatigue , thirst . It investigators hypothesis combination two drug alleviate significantly reduce symptom take start moderate alcohol consumption .</brief_summary>
	<brief_title>Safety Efficacy Combination Product Prevention Veisalgia</brief_title>
	<detailed_description>Some people consume alcohol moderation experience veisalgia . These symptom include long list adverse effect include headache , fatigue thirst . The mechanism effect occur fully elucidate . Although , document alcohol cause release large number substance blood stream cause number physiologic change . A 4-arm study help determine effect agent contribute decrease alcohol induces physiologic change effect two agent deliver concurrently .</detailed_description>
	<mesh_term>Analgesics</mesh_term>
	<mesh_term>Histamine Antagonists</mesh_term>
	<mesh_term>Histamine H1 Antagonists</mesh_term>
	<criteria>Healthy , nonsmoking men woman 25 65 year inclusive Good general health determine thorough medical history physical examination include vital sign Subject selfreported moderate drinker alcohol . Moderate drinking approximate blood alcohol concentration ( BAC ) 0.04 0.11 % . The 0.04 % 0.11 % BAC correlate approximately 120160 pound female drink 2 5 drink 2 3 hour , respectively , 160200 pound male drink 3 7 drink 2 3 hour , respectively . Subject moderate heavy drinking episode past 90 day produce hangover symptom Subject knowledgeable amount alcohol he/she need consume 2 3 hour period time produce hangover symptom Body mass index 19 32 kg/m2 , inclusive Report regular , habitual bedtime 21:30 24:00 Females childbearing potential must use acceptable method contraception ( see Section 8.5 ) surgically sterilize negative urine pregnancy test screen upon admission treatment visit Subject capable understanding requirement study give write informed consent Subject able follow study instruction willing complete study visit procedure Acute illness within 14 day prior screen visit Allergic reaction upper respiratory tract infection within 7 day screen visit Vaccination administration within 7 day screen visit Clinically significant , unstable medical illness Evidence history clinically significant allergic ( except untreated , asymptomatic , seasonal allergy time dose ) , hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic neurological disease History cancer diabetes Subject previous current SubstanceRelated Disorder define DSM5 Selfreport usual consumption 14 unit alcohol per week . One unit alcohol equivalent 12 ounce beer , 4 ounce wine , 1 ounce liquor Selfreport recent ( within one month ) current use smoke chew tobacco product , use nicotine ( e.g. , nicotine gum patch ) Positive alcohol breathalyzer test screen checkin treatment visit Positive urine drug screen screen checkin treatment visit A supine blood pressure &gt; 140/90 mm/Hg screen Heart rate &gt; 100 beat per minute screening Subjects unwilling forgo caffeine consumption follow dinner treatment night unwilling comply study restriction prohibit medications/ food throughout study participation . Clinically significant psychiatric illness , include chronic psychiatric illness history presence Axis I condition Any clinically significant abnormal find physical examination vital sign Positive pregnancy test screen checkin treatment visit Subject previously experience allergic reaction adverse event associate aspirin , NSAIDs , antihistamine usage , include reaction effective Subject take prescription overthecounter oral pain medication ( ) reason Subject take prescription overthecounter antihistamine ( ) Women pregnant breastfeed Any medical condition condition situation investigator 's opinion may put subject significant risk , confound study result , interfere significantly subject 's participation study Concurrent participation investigational drug device study , use investigational drug within 30 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>